ArticleInternational journal of nanomedicine2026
Combination Therapeutic Effect of Asiatic Acid & Curcumin-Loaded Liposomes Modified by Neutrophil Extracellular Traps for the Treatment of Oral Squamous Cell Carcinoma.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor metastasis has been proven to represent the predominant cause of cancer-related mortality; therefore, the strategies simultaneously eradicating primary lesions and blocking dissemination cascades hold revolutionary potential in curative oral squamous cell carcinoma (OSCC) therapy. Methods: In this study, we designed novel neutrophil extracellular traps (NETs)-coating liposomes (CUR@AA-NLIP) for co-delivery of curcumin (CUR) and asiatic acid (AA), in which the introduction of NETs was expected to improve tumor-targeting ability, and the combination of CUR and AA was used to synergistically inhibit tumor development. Results: The characteristics analysis showed that CUR@AA-NLIP exhibited uniform size, phospholipid bilayer structure, and sustained drug release. In vitro studies demonstrated that CUR@AA-NLIP enhanced tumor cell uptake and macrophage escape, inhibited fibroblast activation and vessel tube formation, showing enhanced anti-proliferation and anti-migration capacities. In vivo results confirmed that CUR@AA-NLIP increased drug accumulation in the tumor region, showed enhanced anti-tumor efficacy (> 80% tumor suppression), and reduced lung metastasis. Conclusion: CUR@AA-NLIP holds great potentials in OSCC-targeting delivery of synergistic natural compounds and can achieve anti-proliferative and anti-metastatic effects by simultaneously enhancing tumor accumulation, reducing immune system clearance, and inhibiting of cancer-associated fibroblast (CAF) activation and angiogenesis, therefore exhibiting enhanced anti-OSCC efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.